Join to View Full Profile
4725 E Galbraith RdSte 320Blue Ash, OH 45236
Phone+1 513-751-2273
Fax+1 513-751-1840
Dr. Essell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- James Essell, MD, is an oncologist based in Cincinnati, OH. He graduated from the University of Cincinnati College of Medicine in 1985 and completed his residency and fellowship in Hematology and Medical Oncology at the San Antonio Uniformed Services Health Education Consortium. Dr. Essell specializes in hematologic oncology, stem cell therapy, stem cell transplantation, and general/benign hematology. He has authored multiple peer-reviewed publications, with notable works on therapies for relapsed/refractory lymphoid malignancies,vent-occulsive disease of the liver, acute leukemia and graft-versus-host disease. He has received the Meaningful Use Stage 1 Certification and was recognized as a Top MD by Consumers Checkbook.
Education & Training
San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 1988 - 1991- San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1985 - 1988
University of Cincinnati College of MedicineClass of 1985
Certifications & Licensure
OH State Medical License 1981 - 2027
KY State Medical License 1997 - 2024
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification IntelliDose, IntrinsiQ Specialty Solutions, Inc. FBO Healthtronics Information Technology Solutions Inc., 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2012, 2014-2017
Clinical Trials
- Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2006 Jun 01
- Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
- Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Dec 14
Publications & Presentations
PubMed
- Remote Therapeutic Monitoring and Infection-Related Health Care Resource Utilization in Patients With Hematologic Malignancies.Benjamin A Derman, James H Essell, Mustafa S Ascha, Michael A Kolodziej, Lavi Kwiatkowsky
JCO Oncology Practice. 2026-04-10 - 1 citationsNKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.Sairah Ahmed, John DiPersio, James Essell, Catherine Diefenbach, Miguel-Angel Perales
Blood Advances. 2025-12-09 - 6 citationsLisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani
Blood Advances. 2025-08-12
Press Mentions
Oral Presentation at ASH 2025 Shows Canopy RTM Cuts Infection-Related Hospitalizations by 52% and Generates Nearly $1M in Annual Savings Per 1,000 PatientsDecember 9th, 2025- Canopy Launches Platform-Wide Support for Bispecific AntibodiesSeptember 25th, 2024
- OHC and Jewish Hospital 1st in Region to Offer Revolutionary Cancer Treatment for Multiple MyelomaAugust 13th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
